Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 5/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13521408 | 0.99 | TACR3 (0.41) | TACR3UCHL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13997770 | 0.99 | TACR3 (0.41) | TACR3UCHL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13521221 | 0.99 | TACR3 (0.41) | TACR3UCHL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8275345 | 0.95 | KDM4E (0.41) | TACR3UCHL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12676433 | 0.93 | MCL1 (0.47) | TACR3MCL1 | |
| SCHEMBL13519795 | 0.93 | MCL1 (0.47) | TACR3MCL1 | |
| SCHEMBL13451514 | 0.93 | MCL1 (0.47) | TACR3MCL1 | |
| SCHEMBL13521411 | 0.93 | MCL1 (0.47) | TACR3MCL1 | |
| SCHEMBL8274500 | 0.90 | TACR3 (0.40) | TACR3UCHL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13521409 | 0.90 | TACR3 (0.40) | TACR3UCHL1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316839-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311077-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | TACR3 4636/4885UCHL1 3926/4885KDM4E 2067/4885 |
| US-20060122123-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | TACR3 4636/4885UCHL1 3926/4885KDM4E 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.